A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil

Area of Science:

• Oncology
• Infectious Diseases
• Hematology

Background:

• AIDS-related lymphoma (ARL) poses a significant challenge in HIV-positive patients.
• Prognostic factors for ARL require further elucidation to guide treatment strategies.

Purpose of the Study:

• To develop and validate a prognostic score for patients diagnosed with AIDS-related lymphoma (ARL).
• To assess the score's ability to differentiate risk groups and predict outcomes in ARL patients.

Main Methods:

• Retrospective analysis of 104 ARL patients treated between 1999 and 2007.
• Multivariate analysis identified key survival risk factors (previous AIDS, high-intermediate/high International Prognostic Index).
• A novel risk score was constructed and applied, particularly to diffuse large B-cell lymphoma (DLBC) cases.

Main Results:

• Diffuse large B-cell lymphoma (DLBC) was the predominant subtype (79.8%).
• The 4-year overall survival (OS) rate was 35.8%, with a median survival of 9.7 months.
• The developed risk score clearly distinguished between low, intermediate, and high-risk groups, impacting response rates and OS, especially in DLBC.
• Complete remission (CR) was achieved by 45.8%, with a 4-year disease-free survival (DFS) of 83.0% for those in CR.

Conclusions:

• The novel prognostic score effectively stratifies ARL patients into distinct risk categories.
• Poor immune status and advanced disease stage contribute to reduced survival in this HIV-positive population.
• Further research is needed to optimize treatment for ARL in immunosuppressed patients, potentially identifying candidates for intensive curative-intent therapy.